COVID-19 vaccines in patients with cancer
- PMID: 34087120
- PMCID: PMC8169039
- DOI: 10.1016/S1470-2045(21)00250-3
COVID-19 vaccines in patients with cancer
Conflict of interest statement
GC has received honoraria from Pfizer, Novartis, Lilly, and Roche; fees for expert testimony and medical education from Pfizer; and has participated in advisory boards for Pfizer, Roche, Lilly, Novartis, Seattle Genetics, and Celltrion; all outside the submitted work. DT declares no competing interests.
Comment on
-
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27. Lancet Oncol. 2021. PMID: 33930323 Free PMC article.
References
-
- UK Department of Health and Social Care Optimising the COVID-19 vaccination programme for maximum short-term impact. Independent report. Jan 26, 2021. https://www.gov.uk/government/publications/prioritising-the-first-covid-...